+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multivalent Influenza Vaccines Market - Global Forecast 2026-2032- Product Image
Multivalent Influenza Vaccines Market - Global Forecast 2026-2032- Product Image
Sale

Multivalent Influenza Vaccines Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6151653
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Multivalent Influenza Vaccines Market is projected to reach USD 8.72 Billion in 2026. It is expected to continue growing at a CAGR of 10.44%, reaching USD 15.81 Billion by 2032.

Multivalent Influenza Vaccines: Executive Overview

Multivalent influenza vaccines combine protection against multiple influenza virus strains in a single formulation. Their development and adoption are shaped by seasonal strain evolution, public-health policy, immunization infrastructure, manufacturing capabilities, regulatory requirements, and the need to improve protection across different age and risk groups. This executive summary reviews the principal structural, technological, regional, group, and country-level considerations affecting the market without presenting market estimates or forecasts.

Strain Evolution and Immunization Policy Are Reshaping the Landscape

The landscape is being transformed by the continual evolution of circulating influenza viruses and the resulting need to update vaccine compositions through established global surveillance and strain-selection processes. Public-health agencies increasingly emphasize broader coverage, timely seasonal deployment, vaccination of older adults and people with underlying conditions, and improved access through pharmacies, primary care, occupational programs, and community channels. Manufacturing resilience, egg-based and cell-based production choices, adjuvant use, cold-chain reliability, and regulatory coordination remain central to practical deployment.

Artificial Intelligence Is Strengthening Surveillance, Design, and Operations

Artificial intelligence can support influenza surveillance by identifying patterns in epidemiological, genomic, clinical, and wastewater data, although these applications require rigorous validation and representative datasets. Machine-learning tools may assist strain characterization, antigenic analysis, candidate prioritization, clinical-trial planning, demand coordination, and adverse-event monitoring. The cumulative effect is potentially faster evidence generation and more responsive operations, but human oversight, transparent performance evaluation, data governance, cybersecurity, and regulatory accountability remain essential before AI-supported outputs influence public-health decisions.

Regional Insights: Uneven Preparedness Shapes Adoption and Access

North America is characterized by established seasonal immunization programs, broad provider networks, and substantial regulatory and manufacturing capabilities, while access and uptake can still vary by jurisdiction and population group. Europe benefits from coordinated surveillance and mature public-health systems, but national reimbursement and procurement practices differ. Asia-Pacific combines advanced vaccine ecosystems in some economies with major unmet access and infrastructure needs in others. Latin America is influenced by public-sector procurement, regional disease surveillance, and economic variability. The Middle East reflects differences in health-system capacity, travel-related demand, and immunization policy. Africa remains strongly shaped by financing, supply continuity, cold-chain capacity, surveillance coverage, and the integration of influenza vaccination into broader health programs.

Group Insights: Policy Coordination and Procurement Influence Scale of Impact

ASEAN countries face varied surveillance maturity, manufacturing capacity, and access conditions, making regional coordination and flexible delivery models important. BRICS members span large and diverse populations, with priorities ranging from domestic production and technology transfer to affordability and public-sector coverage. The European Union benefits from shared scientific coordination while retaining nationally distinct purchasing and reimbursement systems. G7 members generally possess strong research, regulatory, and health infrastructure, yet must address aging populations, equity, and vaccine confidence. GCC countries combine comparatively strong health infrastructure with high mobility and expatriate populations, increasing the value of coordinated seasonal planning. NATO members have an additional interest in continuity of healthcare operations and preparedness for cross-border disruptions, while influenza vaccination remains primarily a public-health rather than defense intervention.

Country Insights: Diverse Health Systems Require Tailored Strategies

Australia and Japan have mature immunization systems and strong surveillance capabilities, while South Korea combines advanced healthcare infrastructure with active seasonal vaccination policy. China and India present substantial manufacturing, research, and delivery capacity alongside significant regional variation in access and program implementation. The United States and Canada have broad provider and pharmacy channels, with uptake influenced by public confidence, reimbursement, and jurisdictional policy. Brazil and Mexico rely on large public-health programs and extensive regional coordination. France, Germany, Italy, Spain, and the United Kingdom operate within well-developed regulatory and clinical environments, but differ in eligibility rules, procurement, reimbursement, and delivery settings. Russia’s priorities include domestic supply resilience, surveillance, and national immunization implementation, with outcomes affected by geography and health-system reach.

Actions for Leaders: Build Resilience, Evidence, and Equitable Delivery

Industry leaders should align strain-selection, manufacturing, and inventory decisions with surveillance signals and realistic seasonal timelines. They should diversify critical inputs and production platforms, strengthen quality systems, and maintain contingency plans for disruptions. Evidence strategies should address effectiveness across age and risk groups, real-world outcomes, coadministration, safety, and performance in different delivery settings. Partnerships with public-health agencies, providers, employers, pharmacies, and community organizations can improve access and confidence. AI investments should begin with clearly governed use cases, validated data, human review, and measurable operational outcomes. Finally, organizations should tailor access strategies to local procurement, reimbursement, regulatory, and infrastructure conditions rather than applying a single global model.

Research Methodology: Evidence-Based Review of Market Drivers and Conditions

This executive summary uses the defined multivalent influenza vaccine market scope and organizes findings across technology, epidemiology, policy, manufacturing, delivery, geography, and stakeholder groups. Insights are derived from established public-health and regulatory concepts, including influenza surveillance, seasonal strain selection, vaccination-program design, clinical evidence, production considerations, and health-system access. Regional, group, and country observations are presented qualitatively and are intended to distinguish structural conditions from short-term variation. No market estimates, market sizing, market shares, forecasts, or company-specific claims are included.

Conclusion: Broader Coverage Must Be Matched by Reliable Implementation

Multivalent influenza vaccines sit at the intersection of evolving viral risk, recurring seasonal demand, public-health policy, biotechnology, and healthcare delivery. Their impact will depend not only on formulation and clinical performance, but also on timely strain decisions, resilient manufacturing, equitable procurement, trusted communication, and dependable last-mile access. Leaders that combine scientific discipline with regional adaptation, transparent evidence, and responsible digital innovation will be better positioned to support effective seasonal immunization programs.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Multivalent Influenza Vaccines Market, by Product Type
7.1. Introduction
7.2. Quadrivalent
7.2.1. High Dose
7.2.1.1. Adjuvanted
7.2.1.2. Non Adjuvanted
7.2.2. Standard Dose
7.3. Trivalent
8. Multivalent Influenza Vaccines Market, by Vaccine Type
8.1. Introduction
8.2. Inactivated
8.2.1. Split Virus
8.2.2. Subunit
8.3. Live Attenuated
8.4. Recombinant
9. Multivalent Influenza Vaccines Market, by Technology Platform
9.1. Introduction
9.2. Cell Based
9.2.1. MDCK Culture
9.2.2. Vero Culture
9.3. Egg Based
9.4. Recombinant
10. Multivalent Influenza Vaccines Market, by Route Of Administration
10.1. Introduction
10.2. Intradermal
10.3. Intramuscular
10.4. Intranasal
11. Multivalent Influenza Vaccines Market, by Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Multivalent Influenza Vaccines Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.4. Pharmacy
12.5. Public Health Agencies
13. Multivalent Influenza Vaccines Market, by Distribution Channel
13.1. Introduction
13.2. Direct Purchase
13.3. Government Tender
13.4. Retail Pharmacy
13.5. Wholesale Distribution
14. Multivalent Influenza Vaccines Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. Multivalent Influenza Vaccines Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. Multivalent Influenza Vaccines Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AstraZeneca plc
18.2. Bharat Biotech International Limited
18.3. BioNTech SE
18.4. CSL Limited
18.5. CureVac N.V.
18.6. Dynavax Technologies Corporation
18.7. GlaxoSmithKline plc
18.8. Inovio Pharmaceuticals Inc.
18.9. KM Biologics Co., Ltd.
18.10. Medicago Inc.
18.11. Merck & Co., Inc.
18.12. Moderna Inc.
18.13. Novartis AG
18.14. Novavax Inc.
18.15. Pfizer Inc.
18.16. Sanofi S.A.
18.17. Seqirus USA, Inc.
18.18. Takeda Pharmaceutical Company Limited
18.19. Zydus Cadila Limited
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global Multivalent Influenza Vaccines Market, Years Considered for the Study
FIGURE 2. Global Multivalent Influenza Vaccines Market, Research Design
FIGURE 3. Global Multivalent Influenza Vaccines Market, Research Framework
FIGURE 4. Global Multivalent Influenza Vaccines Market, Data Triangulation
FIGURE 5. Global Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Multivalent Influenza Vaccines Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Multivalent Influenza Vaccines Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2025 vs 2032 (%)
FIGURE 9. Global Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Multivalent Influenza Vaccines Market Size, by Technology Platform, 2025 vs 2032 (%)
FIGURE 11. Global Multivalent Influenza Vaccines Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 13. Global Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Multivalent Influenza Vaccines Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 15. Global Multivalent Influenza Vaccines Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Multivalent Influenza Vaccines Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Multivalent Influenza Vaccines Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 19. Global Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Multivalent Influenza Vaccines Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global Multivalent Influenza Vaccines Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Multivalent Influenza Vaccines Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Multivalent Influenza Vaccines Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global Multivalent Influenza Vaccines Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Multivalent Influenza Vaccines Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Multivalent Influenza Vaccines Market Segmentation & Coverage
TABLE 2. Global Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
TABLE 3. Global Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Quadrivalent Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Quadrivalent Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Quadrivalent Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global High Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global High Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global High Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Adjuvanted Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Adjuvanted Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Adjuvanted Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Non Adjuvanted Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Non Adjuvanted Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Non Adjuvanted Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Standard Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Standard Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Standard Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Trivalent Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Trivalent Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Trivalent Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 23. Global Inactivated Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Inactivated Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Inactivated Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Split Virus Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Split Virus Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Split Virus Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Subunit Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Subunit Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Subunit Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 39. Global Cell Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Cell Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Cell Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global MDCK Culture Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global MDCK Culture Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global MDCK Culture Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Vero Culture Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Vero Culture Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Vero Culture Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Egg Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Egg Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Egg Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 55. Global Intradermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Intradermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Intradermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Intranasal Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Intranasal Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Intranasal Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 65. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Public Health Agencies Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Public Health Agencies Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Public Health Agencies Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Global Direct Purchase Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Direct Purchase Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Direct Purchase Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Government Tender Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Government Tender Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Government Tender Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Wholesale Distribution Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Wholesale Distribution Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Wholesale Distribution Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. North America Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. North America Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 115. North America Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 116. North America Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 117. North America Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 118. North America Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 119. North America Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 120. North America Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 121. North America Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 122. North America Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 123. North America Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. North America Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 125. Latin America Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Latin America Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 127. Latin America Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 128. Latin America Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 129. Latin America Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 130. Latin America Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 131. Latin America Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 132. Latin America Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 133. Latin America Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. Latin America Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 135. Latin America Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. Latin America Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. Europe Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Europe Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 139. Europe Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 140. Europe Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 141. Europe Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 142. Europe Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 143. Europe Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 144. Europe Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 145. Europe Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 146. Europe Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 147. Europe Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. Europe Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 149. Middle East Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Middle East Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 151. Middle East Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 152. Middle East Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 153. Middle East Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 154. Middle East Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 155. Middle East Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 156. Middle East Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 157. Middle East Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. Middle East Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 159. Middle East Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Middle East Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. Africa Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Africa Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 163. Africa Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 164. Africa Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 165. Africa Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 166. Africa Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 167. Africa Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 168. Africa Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 169. Africa Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 170. Africa Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 171. Africa Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. Africa Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 173. Global Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 174. ASEAN Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. ASEAN Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 176. ASEAN Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 177. ASEAN Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 178. ASEAN Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 179. ASEAN Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 180. ASEAN Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 181. ASEAN Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 182. ASEAN Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 183. ASEAN Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 184. ASEAN Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. ASEAN Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. GCC Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. GCC Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 188. GCC Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 189. GCC Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 190. GCC Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 191. GCC Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 192. GCC Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 193. GCC Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 194. GCC Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 195. GCC Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 196. GCC Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. GCC Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. European Union Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 199. European Union Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 200. European Union Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 201. European Union Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 202. European Union Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 203. European Union Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 204. European Union Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 205. European Union Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 206. European Union Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. European Union Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 208. European Union Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. European Union Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. BRICS Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 211. BRICS Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 212. BRICS Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 213. BRICS Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 214. BRICS Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 215. BRICS Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 216. BRICS Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 217. BRICS Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 218. BRICS Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 219. BRICS Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 220. BRICS Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. BRICS Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 222. G7 Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 223. G7 Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 224. G7 Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 225. G7 Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 226. G7 Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 227. G7 Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 228. G7 Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 229. G7 Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 230. G7 Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 231. G7 Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 232. G7 Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. G7 Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. NATO Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 235. NATO Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 236. NATO Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 237. NATO Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 238. NATO Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 239. NATO Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 240. NATO Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 241. NATO Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 242. NATO Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 243. NATO Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 244. NATO Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. NATO Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 246. Global Multivalent Influenza Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 247. United States Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
TABLE 248. United States Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 249. United States Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 250. United States Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 251. United States Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 252. United States Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 253. United States Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 254. United States Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 255. United States Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 256. United States Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 257. United States Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 258. United States Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. Canada Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
TABLE 260. Canada Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 261. Canada Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 262. Canada Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 263. Canada Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 264. Canada Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 265. Canada Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 266. Canada Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 267. Canada Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 268. Canada Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 269. Canada Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 270. Canada Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 271. Mexico Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
TABLE 272. Mexico Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 273. Mexico Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 274. Mexico Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 275. Mexico Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 276. Mexico Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 277. Mexico Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 278. Mexico Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 279. Mexico Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 280. Mexico Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 281. Mexico Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 282. Mexico Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 283. Brazil Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
TABLE 284. Brazil Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 285. Brazil Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 286. Brazil Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 287. Brazil Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 288. Brazil Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 289. Brazil Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 290. Brazil Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 291. Brazil Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 292. Brazil Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 293. Brazil Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 294. Brazil Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. United Kingdom Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
TABLE 296. United Kingdom Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 297. United Kingdom Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 298. United Kingdom Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 299. United Kingdom Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 300. United Kingdom Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 301. United Kingdom Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 302. United Kingdom Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 303. United Kingdom Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 304. United Kingdom Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 305. United Kingdom Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 306. United Kingdom Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 307. Germany Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
TABLE 308. Germany Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 309. Germany Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 310. Germany Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 311. Germany Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 312. Germany Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 313. Germany Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 314. Germany Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 315. Germany Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 316. Germany Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 317. Germany Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 318. Germany Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 319. France Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
TABLE 320. France Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 321. France Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 322. France Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 323. France Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 324. France Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 325. France Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 326. France Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
TABLE 327. France Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 328. France Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 329. France Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 330. France Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 331. Russia Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
TABLE 332. Russia Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 333. Russia Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
TABLE 334. Russia Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
TABLE 335. Russia Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 336. Russia Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
TABLE 337. Russ

Companies Mentioned

  • AstraZeneca plc
  • Bharat Biotech International Limited
  • BioNTech SE
  • CSL Limited
  • CureVac N.V.
  • Dynavax Technologies Corporation
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals Inc.
  • KM Biologics Co., Ltd.
  • Medicago Inc.
  • Merck & Co., Inc.
  • Moderna Inc.
  • Novartis AG
  • Novavax Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Seqirus USA, Inc.
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila Limited

Related Topics

Related Reports

Avian Influenza Vaccine Market - Global Strategic Business Report - Product Image

Avian Influenza Vaccine Market - Global Strategic Business Report

  • Report
  • 286 Pages
  • Global
From
Influenza Vaccine Market - Global Forecast 2026-2032 - Product Image

Influenza Vaccine Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Avian Influenza Vaccines Market - Global Forecast 2026-2032 - Product Image

Avian Influenza Vaccines Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Influenza Vaccines - Global Strategic Business Report - Product Image

Influenza Vaccines - Global Strategic Business Report

  • Report
  • 554 Pages
  • Global
From
Influenza Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Influenza Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 112 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.